Published by Josh White on 13th January 2025
(Sharecast News) - Cell-engineering platform technology company MaxCyte said in an update on Friday that it expected core revenue for the fourth quarter to range between $8.3m and $8.5m, up from $7.2m in the same period last year.
URL: http://www.digitallook.com/dl/news/story/34807958/...